Bayer AG (MEX:BAYN)
MXN 570 0 (0%) Market Cap: 389.84 Bil Enterprise Value: 1.07 Til PE Ratio: 0 PB Ratio: 0.61 GF Score: 56/100

Bayer AG at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 07:15PM GMT
Release Date Price: MXN590.25
Richard Vosser
JPMorgan Chase & Co, Research Division - Senior Analyst

Welcome to the Bayer session at the 42nd JPMorgan Health Care Conference. I'm Richard Vosser, European pharma analyst with JPMorgan. It's my great pleasure to welcome the CEO of the Pharma business at Bayer Stefan Orrick, who's going to present to us. We'll take questions after his presentation. So just please put your hand up, and we'll get a mic to you. Stefan, welcome to the conference.

Stefan Oelrich
Bayer Aktiengesellschaft - Head of the Pharmaceuticals Division & Member of the Board of Management

Well, thank you, Richard, and thank you for your interest in our business here, glad to see that the room is filling up fast. So I'm going to give you a little overview on how we're proceeding well with the implementation of our strategy. But before I get to that, we're really excited this week because we've had tremendous news flow with our latest Phase III trial, giving positive primary and secondary endpoints in 2 parallel trials, an approval for EYLEA in Europe, which was sort of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot